bupropion and Dyslipidemias

bupropion has been researched along with Dyslipidemias in 3 studies

Bupropion: A propiophenone-derived antidepressant and antismoking agent that inhibits the uptake of DOPAMINE.
bupropion : An aromatic ketone that is propiophenone carrying a tert-butylamino group at position 2 and a chloro substituent at position 3 on the phenyl ring.

Dyslipidemias: Abnormalities in the serum levels of LIPIDS, including overproduction or deficiency. Abnormal serum lipid profiles may include high total CHOLESTEROL, high TRIGLYCERIDES, low HIGH DENSITY LIPOPROTEIN CHOLESTEROL, and elevated LOW DENSITY LIPOPROTEIN CHOLESTEROL.

Research

Studies (3)

Authors

Clinical Trials (1)

Trial Overview

Trial Outcomes

Body Weight- Mean Percent Change From Baseline to Week 56

"Beginning at Week 28 through Week 44, NB32-treated subjects who failed to achieve or maintain at least 5% body weight loss from baseline were re-randomized (1:1 ratio) to continue NB32 or begin treatment with a higher dose of naltrexone SR - naltrexone SR 48 mg/bupropion SR 360 mg (referred to as NB48) (daily dose of bupropion SR was 360 mg for NB32 and NB48).The analysis of NB32 vs. placebo at Week 56 was completed using a weighted analysis. This analysis was referred to as the weighted LOCF analysis.~Subjects treated with NB32 who were re-randomized to NB48 were not included. Subjects re-randomized to NB32 were double-weighted and subjects who were not re-randomized were single-weighted. Subjects in the placebo group were single-weighted. The double weighting analysis restored the influence of poor performers at Weeks 28 to 44 in the NB32 group without including any data from the higher dose group (NB48)." (NCT00567255)
Timeframe: Baseline, 56 weeks

Body Weight- Proportion of Subjects With ≥10% Decrease From Baseline to Week 28

(NCT00567255)
Timeframe: Baseline, 28 weeks

Body Weight- Proportion of Subjects With ≥5% Decrease From Baseline to Week 56

"Beginning at Week 28 through Week 44, NB32-treated subjects who failed to achieve or maintain at least 5% body weight loss from baseline were re-randomized (1:1 ratio) to continue NB32 or begin treatment with a higher dose of naltrexone SR - naltrexone SR 48 mg/bupropion SR 360 mg (referred to as NB48) (daily dose of bupropion SR was 360 mg for NB32 and NB48).The analysis of NB32 vs. placebo at Week 56 was completed using a weighted analysis. This analysis was referred to as the weighted LOCF analysis.~Subjects treated with NB32 who were re-randomized to NB48 were not included. Subjects re-randomized to NB32 were double-weighted and subjects who were not re-randomized were single-weighted. Subjects in the placebo group were single-weighted. The double weighting analysis restored the influence of poor performers at Weeks 28 to 44 in the NB32 group without including any data from the higher dose group (NB48)." (NCT00567255)
Timeframe: Baseline, 56 weeks

Change in Diastolic Blood Pressure

(NCT00567255)
Timeframe: Baseline, 28 weeks

Change in Fasting Blood Glucose Levels

(NCT00567255)
Timeframe: Baseline, 28 weeks

Change in Fasting HDL Cholesterol Levels

(NCT00567255)
Timeframe: Baseline, 28 weeks

Change in Fasting Insulin Levels, Using Log-transformed Data

(NCT00567255)
Timeframe: Baseline, 28 weeks

Change in Fasting LDL Cholesterol Levels

(NCT00567255)
Timeframe: Baseline, 28 weeks

Change in Fasting Triglycerides Levels, Using Log-transformed Data

(NCT00567255)
Timeframe: Baseline, 28 weeks

Change in Food Craving Inventory Carbohydrates Subscale Score

The Food Craving Inventory is a 33-item self-report measure designed to assess specific food cravings and is organized into 4 subscales (high fats, sweets, carbohydrates/starches, and fast-food fats). A craving was defined as an intense desire to consume a particular food (or food type) that was difficult to resist over the past month. Subjects rated their frequency of cravings for each of the 33 items using a 5-point scale, where 1=never, 2=rarely, 3=sometimes, 4=often, and 5=always. The carbohydrates subscale consisted of 8 items and the score ranges from 8 (better outcome) to 40 (worse outcome). (NCT00567255)
Timeframe: Baseline, 28 weeks

Change in Food Craving Inventory Sweets Subscale Score

The Food Craving Inventory is a 33-item self-report measure designed to assess specific food cravings and is organized into 4 subscales (high fats, sweets, carbohydrates/starches, and fast-food fats). A craving was defined as an intense desire to consume a particular food (or food type) that was difficult to resist over the past month. Subjects rated their frequency of cravings for each of the 33 items using a 5-point scale, where 1=never, 2=rarely, 3=sometimes, 4=often, and 5=always. The sweets subscale consisted of 8 items and the score ranges from 8 (better outcome) to 40 (worse outcome). (NCT00567255)
Timeframe: Baseline, 28 weeks

Change in High-sensitivity C Reactive Protein (Hs-CRP) Levels, Using Log-transformed Data

(NCT00567255)
Timeframe: Baseline, 28 weeks

Change in HOMA-IR Levels, Using Log-transformed Data

HOMA-IR= Homeostasis Model Assessment-Insulin Resistance (NCT00567255)
Timeframe: Baseline, 28 weeks

Change in IDS-SR Total Score

IDS-SR= Inventory of Depressive Symptoms-Subject Rated IDS-SR total score is based on 30 items. The total score can range from 0-84, with 0 being no depressive symptoms and 84 being very severe depressive symptoms. A total score ≤ 13 indicates no depression. (NCT00567255)
Timeframe: Baseline, 28 weeks

Change in IWQOL-Lite Total Scores

IWQOL-Lite= Impact of Weight on Quality of Life-Lite Questionnaire Total score is based on a scale from 0 to 100, with 0 representing the poorest and 100 the best quality of life and where a score of 71-79 indicates moderate impairment (NCT00567255)
Timeframe: Baseline, 28 weeks

Change in Question 19 From 21-Item COE (Control of Eating) Questionnaire

Question 19: Generally, how difficult has it been to control your eating? Scoring: 0=not at all difficult; 100=extremely difficult (NCT00567255)
Timeframe: Baseline, 28 weeks

Change in Systolic Blood Pressure

(NCT00567255)
Timeframe: Baseline, 28 weeks

Change in Waist Circumference

(NCT00567255)
Timeframe: Baseline, 28 weeks

Co-primary: Body Weight- Mean Percent Change From Baseline to Week 28

(NCT00567255)
Timeframe: Baseline, 28 weeks

Co-primary: Body Weight- Proportion of Subjects With ≥5% Decrease From Baseline to Week 28

(NCT00567255)
Timeframe: Baseline, 28 weeks

Reviews

1 review available for bupropion and Dyslipidemias

Trials

2 trials available for bupropion and Dyslipidemias